OncoMatch/Bile Duct Cancer (Cholangiocarcinoma)/HER2 (ERBB2)
Bile Duct Cancer (Cholangiocarcinoma)HER2 (ERBB2) Clinical Trials
HER2 amplification or overexpression occurs in approximately 5–10% of biliary tract cancers and is now an actionable therapeutic target. Zanidatamab, a bispecific HER2 antibody, is FDA accelerated-approved for previously treated unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. Trials investigate zanidatamab combinations, trastuzumab deruxtecan (T-DXd), and other HER2-directed agents with checkpoint inhibitors across amplification levels.
Top recruiting HER2 (ERBB2) Bile Duct Cancer (Cholangiocarcinoma) trials
Ranked by phase and US site count.
See all trials matched to your profile →Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
AstraZeneca
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
Tata Memorial Centre
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Phanes Therapeutics
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Beijing Biotech
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer
Peking Union Medical College Hospital